Skip to content
Homepage
Author:
SK pharmteco Inc.
Posted Date:
June 23, 2026
SK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedside
SK pharmteco Inc.
June 23, 2026
SK pharmteco Announces Strategic Collaboration with Orphan Therapeutics Accelerator for the Development and Manufacturing of Rare Disease Therapies
SK pharmteco Inc.
June 18, 2026
SK pharmteco Collaborates with Axle Informatics and the National Institutes of Health to Advance Rare Disease Gene Therapy Programs
SK pharmteco Inc.
May 7, 2026
SK pharmteco Achieves SBTi Validation for 2040 Net-Zero Science-Based Targets
SK pharmteco Inc.
May 5, 2026
SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts
SK pharmteco Inc.
March 26, 2026
SK pharmteco and Prozomix Announce Strategic Collaboration to Enhance Biocatalysis Capabilities for Global Drug Manufacturing
SK pharmteco Inc.
March 24, 2026
SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment
SK pharmteco Inc.
March 19, 2026
SK pharmteco Announces Successful FDA Inspection of Small Molecule Manufacturing Facility in La Porte, Texas
SK pharmteco Inc.
March 17, 2026
SK pharmteco Announces CGMP Qualification of its Commercial-Scale Viral Vector Manufacturing Facility in France
SK pharmteco Inc.
March 12, 2026
